Skip to content
2000
Volume 20, Issue 2
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

The design and development of radiolabelled steroid derivatives has been an important area of research due to their wellknown value in breast cancer targeting. The estrogen receptor (ER) and progesterone receptor (PR) are important biomarkers in the diagnosis, prognosis and follow-up of the therapeutic response of breast tumours. Thus, several radioligands based on estrogens and progestins have been proposed for targeted functional ER imaging. The aim of this review is to survey and analyze the developments in this field, which have led to the design of a number of PET steroid-based imaging agents, a few of which seem to be promising as radiopharmaceuticals for detection of ER-positive breast tumours.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867311320020004
2013-01-01
2025-05-05
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867311320020004
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test